Abstract
Cannabinoids are the most commonly abused illicit drugs worldwide. While cannabis can be beneficial for certain heath conditions, abuse of potent synthetic cannabinoids has been on the rise. Exposure to cannabinoids is also prevalent in women of child-bearing age and pregnant women. These compounds can cross the placental barrier and directly affect the fetus. They mediate their effects primarily through G-protein coupled cannabinoid receptors, CB1 and CB2. In addition to significant neurological effects, cannabinoids can trigger robust immunomodulation by altering cytokine levels, causing apoptosis of lymphoid cells and inducing suppressor cells of the immune system. Profound effects of cannabinoids on the immune system as discussed in this review, suggest that maternal exposure during pregnancy could lead to dysregulation of innate and adaptive immune system of developing fetus and offspring potentially leading to weakening of immune defenses against infections and cancer later in life. Emerging evidence also indicates the underlying role of epigenetic mechanisms causing long-lasting impact following cannabinoid exposure in utero.
Similar content being viewed by others
References
Hall W, Degenhardt L (2007) Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 20:393–397. https://doi.org/10.1097/YCO.0b013e32812144cc
NIDA (2018) Drug facts: Marijuana. National Institute on Drug Abuse, Bethesda. https://www.drugabuse.gov/publications/drugfacts/marijuana. Accessed 31 Aug 2018
Freund SA, Banning AS (2017) Synthetic cannabinoids: a review of the clinical implications of a new drug of choice. JAAPA 30:1–4. https://doi.org/10.1097/01.JAA.0000525914.28344.e2
Schrot RJ, Hubbard JR (2016) Cannabinoids: medical implications. Ann Med 48:128–141. https://doi.org/10.3109/07853890.2016.1145794
Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474–2483. https://doi.org/10.1001/jama.2015.6199
Murray RM, Morrison PD, Henquet C, Di Forti M (2007) Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8:885–895. https://doi.org/10.1038/nrn2253
Svrakic DM, Lustman PJ, Mallya A et al (2012) Legalization, decriminalization and medicinal use of cannabis: a scientific and public health perspective. Mol Med 109:90–98
Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614. https://doi.org/10.1046/j.1360-0443.1996.911115852.x
ElSohly MA, Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539–548. https://doi.org/10.1016/j.lfs.2005.09.011
Zuardi AW, Crippa JAS, Hallak JEC et al (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18:5131–5140
Di Marzo V, Petrocellis LD (2006) Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 57:553–574. https://doi.org/10.1146/annurev.med.57.011205.135648
Friedman D, Devinsky O (2015) Cannabinoids in the treatment of epilepsy. N Engl J Med 373:1048–1058. https://doi.org/10.1056/NEJMra1407304
Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367:3353–3363. https://doi.org/10.1098/rstb.2011.0381
Nagarkatti P, Pandey R, Rieder SA et al (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1:1333–1349. https://doi.org/10.4155/fmc.09.93
WHO (2016) Management of substance abuse: Cannabis. World Health Organisation. http://www.who.int/substance_abuse/facts/cannabis/en.2016. Accessed 31 Aug 2018
Johnston L, O’Malley P, Bachman J, Schulenberg J (2012) Monitoring the Future national results on adolescent drug use: overview of key findings, 2011. Institute for Social Research, The University of Michigan, Ann Arbor
Azofeifa A, Mattson ME, Schauer G et al (2016) National estimates of marijuana use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill Summ 65:1–28. https://doi.org/10.15585/mmwr.ss6511a1
SAMHSA (2017) Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Methodological resource book (Section 13, Statistical inference report). Substance Abuse and Mental Health Services Administration, Rockville. https://www.samhsa.gov/data. Accessed 31 Aug 2018
NIDA (2018) Drug facts: synthetic cannabinoids (K2/Spice). National Institute on Drug Abuse. https://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids-k2spice. Accessed 30 Mar 2018
Wu L-T, Zhu H, Swartz MS (2016) Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend 165:181–190. https://doi.org/10.1016/j.drugalcdep.2016.06.002
Bridgeman MB, Abazia DT (2017) Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T 42:180–188
Cascini F, Aiello C, Di Tanna G (2012) Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5:32–40
Loeffler G, Delaney E, Hann M (2016) International trends in spice use: prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Brain Res Bull 126:8–28. https://doi.org/10.1016/j.brainresbull.2016.04.013
Palamar JJ, Acosta P (2015) Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug Alcohol Depend 149:194–202. https://doi.org/10.1016/j.drugalcdep.2015.01.044
Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60. https://doi.org/10.3389/fnbeh.2011.00060
Castaneto MS, Gorelick DA, Desrosiers NA et al (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41. https://doi.org/10.1016/j.drugalcdep.2014.08.005
Cooper ZD (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 18:52. https://doi.org/10.1007/s11920-016-0694-1
Gudsoorkar VS, Perez JA (2015) A new differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J 11:189–191. https://doi.org/10.14797/mdcj-11-3-189
Ford BM, Tai S, Fantegrossi WE, Prather PL (2017) Synthetic pot: not your grandfather’s marijuana. Trends Pharmacol Sci 38:257–276. https://doi.org/10.1016/j.tips.2016.12.003
Felder CC, Joyce KE, Briley EM et al (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450
Grotenhermen F (2004) Pharmacology of cannabinoids. Neuro Endocrinol Lett 25:14–23
Johnston M, O’Malley P, Bachman J (2000) Monitoring the future national survey results on drug use, 1975–1999. Volume II: College Students and Adults Ages 19–40. National Institute of Drug Abuse, Rockville. http://www.monitoringthefuture.org/pubs.html. Accessed 5 Oct 2018
Ebrahim SH, Gfroerer J (2003) Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol 101:374–379
Lipari RN, Hedden SL, Hughes A (2013) Substance use and mental health estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings. In: The CBHSQ Report. Substance Abuse and Mental Health Services Administration (US), Rockville
Gunn JKL, Rosales CB, Center KE et al (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 6:e009986. https://doi.org/10.1136/bmjopen-2015-009986
SAMHSA (2014) Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Substance Abuse and Mental Health Services Administration, Rockville
Martin CE, Longinaker N, Mark K et al (2015) Recent trends in treatment admissions for marijuana use during pregnancy. J Addict Med 9:99–104. https://doi.org/10.1097/ADM.0000000000000095
Braillon A, Bewley S (2018) Committee Opinion No. 722: marijuana use during pregnancy and lactation. Obstet Gynecol 131:164. https://doi.org/10.1097/AOG.0000000000002429
Brancato A, Cannizzaro C (2018) Mothering under the influence: how perinatal drugs of abuse alter the mother–infant interaction. Rev Neurosci 29:283–294. https://doi.org/10.1515/revneuro-2017-0052
Alpár A, Di Marzo V, Harkany T (2016) At the tip of an iceberg: prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biol Psychiatry 79:e33–e45. https://doi.org/10.1016/j.biopsych.2015.09.009
Campolongo P, Trezza V, Palmery M et al (2009) Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol 85:117–133. https://doi.org/10.1016/S0074-7742(09)85009-5
Hayatbakhsh MR, Flenady VJ, Gibbons KS et al (2012) Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 71:215–219. https://doi.org/10.1038/pr.2011.25
Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL (2009) Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci 259:395–412. https://doi.org/10.1007/s00406-009-0027-z
Wang X, Dow-Edwards D, Anderson V et al (2004) In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56:909–915. https://doi.org/10.1016/j.biopsych.2004.10.015
Brancato A, Lavanco G, Cavallaro A et al (2016) The use of the emotional-object recognition as an assay to assess learning and memory associated to an aversive stimulus in rodents. J Neurosci Methods 274:106–115. https://doi.org/10.1016/j.jneumeth.2016.09.010
Brancato A, Cavallaro A, Lavanco G et al (2018) Reward-related limbic memory and stimulation of the cannabinoid system: an upgrade in value attribution? J Psychopharmacol (Oxford) 32:204–214. https://doi.org/10.1177/0269881117725683
Fergusson DM, Horwood LJ, Northstone K, ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood (2002) Maternal use of cannabis and pregnancy outcome. BJOG 109:21–27
Metz TD, Allshouse AA, Hogue CJ et al (2017) Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. Am J Obstet Gynecol 217:478.e1–478.e8. https://doi.org/10.1016/j.ajog.2017.05.050
De Petrocellis L, Cascio MG, Di Marzo V (2004) The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765–774. https://doi.org/10.1038/sj.bjp.0705666
Devane WA (1994) New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 15:40–41
Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1–18
Luchicchi A, Pistis M (2012) Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 46:374–392. https://doi.org/10.1007/s12035-012-8299-0
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347–1356. https://doi.org/10.1016/j.chembiol.2007.11.006
Cravatt BF, Giang DK, Mayfield SP et al (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83–87. https://doi.org/10.1038/384083a0
Bari M, Battista N, Pirazzi V, Maccarrone M (2011) The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci (Landmark Ed) 16:498–516
Taylor AH, Amoako AA, Bambang K et al (2010) Endocannabinoids and pregnancy. Clin Chim Acta 411:921–930. https://doi.org/10.1016/j.cca.2010.03.012
Battista N, Pasquariello N, Di Tommaso M, Maccarrone M (2008) Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction. J Neuroendocrinol 20(Suppl 1):82–89. https://doi.org/10.1111/j.1365-2826.2008.01684.x
Taylor AH, Ang C, Bell SC, Konje JC (2007) The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum Reprod Update 13:501–513. https://doi.org/10.1093/humupd/dmm018
Fride E (2008) Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development. J Neuroendocrinol 20(Suppl 1):75–81. https://doi.org/10.1111/j.1365-2826.2008.01670.x
Maccarrone M, Valensise H, Bari M et al (2000) Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355:1326–1329. https://doi.org/10.1016/S0140-6736(00)02115-2
Maccarrone M, Bisogno T, Valensise H et al (2002) Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod 8:188–195
Habayeb OMH, Taylor AH, Bell SC et al (2008) Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology 149:5052–5060. https://doi.org/10.1210/en.2007-1799
Maccarrone M, Finazzi-Agrò A (2004) Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 25:353–357. https://doi.org/10.1016/j.tips.2004.05.002
Schmid PC, Paria BC, Krebsbach RJ et al (1997) Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 94:4188–4192
Almada M, Amaral C, Diniz-da-Costa M et al (2016) The endocannabinoid anandamide impairs in vitro decidualization of human cells. Reproduction 152:351–361. https://doi.org/10.1530/REP-16-0364
Fonseca BM, Correia-da-Silva G, Teixeira NA (2015) Anandamide restricts uterine stromal differentiation and is critical for complete decidualization. Mol Cell Endocrinol 411:167–176. https://doi.org/10.1016/j.mce.2015.04.024
Schuel H, Burkman LJ, Lippes J et al (2002) Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev 63:376–387. https://doi.org/10.1002/mrd.90021
McIntosh AL, Martin GG, Huang H et al (2018) Δ9-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by Fabp1 gene ablation. J Lipid Res 59:646–657. https://doi.org/10.1194/jlr.M082644
Leishman E, Murphy M, Mackie K, Bradshaw HB (2018) Δ9-Tetrahydrocannabinol changes the brain lipidome and transcriptome differentially in the adolescent and the adult. Biochim Biophys Acta Mol Cell Biol Lipids 1863:479–492. https://doi.org/10.1016/j.bbalip.2018.02.001
Karasu T, Marczylo TH, Maccarrone M, Konje JC (2011) The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum Reprod Update 17:347–361. https://doi.org/10.1093/humupd/dmq058
Maia J, Almada M, Silva A et al (2017) The endocannabinoid system expression in the female reproductive tract is modulated by estrogen. J Steroid Biochem Mol Biol 174:40–47. https://doi.org/10.1016/j.jsbmb.2017.07.023
Maccarrone M, Di Rienzo M, Finazzi-Agrò A, Rossi A (2003) Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J Biol Chem 278:13318–13324. https://doi.org/10.1074/jbc.M211248200
Maccarrone M, Bari M, Di Rienzo M et al (2003) Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 278:32726–32732. https://doi.org/10.1074/jbc.M302123200
Maccarrone M, Valensise H, Bari M et al (2001) Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 166:7183–7189
Bambang KN, Lambert DG, Lam PMW et al (2012) Immunity and early pregnancy events: are endocannabinoids the missing link? J Reprod Immunol 96:8–18. https://doi.org/10.1016/j.jri.2012.10.003
Psychoyos D, Vinod KY (2013) Marijuana, Spice “herbal high”, and early neural development: implications for rescheduling and legalization. Drug Test Anal 5:27–45. https://doi.org/10.1002/dta.1390
Psychoyos D, Vinod KY, Cao J et al (2012) Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95:137–150. https://doi.org/10.1002/bdrb.20348
Oh H-A, Kwon S, Choi S et al (2013) Uncovering a role for endocannabinoid signaling in autophagy in preimplantation mouse embryos. Mol Hum Reprod 19:93–101. https://doi.org/10.1093/molehr/gas049
Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM (2003) The immunology of successful pregnancy. Hum Reprod Update 9:347–357
Tafuri A, Alferink J, Möller P et al (1995) T cell awareness of paternal alloantigens during pregnancy. Science 270:630–633
Trundley A, Moffett A (2004) Human uterine leukocytes and pregnancy. Tissue Antigens 63:1–12
Luppi P, Haluszczak C, Trucco M, Deloia JA (2002) Normal pregnancy is associated with peripheral leukocyte activation. Am J Reprod Immunol 47:72–81
Luppi P, Haluszczak C, Betters D et al (2002) Monocytes are progressively activated in the circulation of pregnant women. J Leukoc Biol 72:874–884
Ueda Y, Hagihara M, Okamoto A et al (2003) Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. Hum Immunol 64:1144–1151
Shi Y, Ling B, Zhou Y et al (2007) Interferon-gamma expression in natural killer cells and natural killer T cells is suppressed in early pregnancy. Cell Mol Immunol 4:389–394
Harbison RD, Mantilla-Plata B (1972) Prenatal toxicity, maternal distribution and placental transfer of tetrahydrocannabinol. J Pharmacol Exp Ther 180:446–453
Vardaris RM, Weisz DJ, Fazel A, Rawitch AB (1976) Chronic administration of delta-9-tetrahydrocannabinol to pregnant rats: studies of pup behavior and placental transfer. Pharmacol Biochem Behav 4:249–254
Blackard C, Tennes K (1984) Human placental transfer of cannabinoids. N Engl J Med 311:797. https://doi.org/10.1056/NEJM198409203111213
Bailey JR, Cunny HC, Paule MG, Slikker W (1987) Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90:315–321
El Marroun H, Tiemeier H, Steegers EAP et al (2009) Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry 48:1173–1181. https://doi.org/10.1097/CHI.0b013e3181bfa8ee
Hurd YL, Wang X, Anderson V et al (2005) Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol 27:221–229. https://doi.org/10.1016/j.ntt.2004.11.002
Murphy LL, Gher J, Szary A (1995) Effects of prenatal exposure to delta-9-tetrahydrocannabinol on reproductive, endocrine and immune parameters of male and female rat offspring. Endocrine 3:875–879. https://doi.org/10.1007/BF02738892
Cabral GA, Rogers TJ, Lichtman AH (2015) Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol 10:193–203. https://doi.org/10.1007/s11481-015-9615-z
Roth MD, Baldwin GC, Tashkin DP (2002) Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 121:229–239
Kaminski NE (1996) Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol 52:1133–1140
Klein TW, Newton C, Larsen K et al (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486–496. https://doi.org/10.1189/jlb.0303101
Galiègue S, Mary S, Marchand J et al (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61
Howlett AC, Bidaut-Russell M, Devane WA et al (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 13:420–423
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65. https://doi.org/10.1038/365061a0
Kenney SP, Kekuda R, Prasad PD et al (1999) Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 181:491–497
Dennedy MC, Friel AM, Houlihan DD et al (2004) Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol 190:2–9. https://doi.org/10.1016/j.ajog.2003.07.013
Das SK, Paria BC, Chakraborty I, Dey SK (1995) Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 92:4332–4336
El-Talatini MR, Taylor AH, Elson JC et al (2009) Localisation and function of the endocannabinoid system in the human ovary. PLoS One 4:e4579. https://doi.org/10.1371/journal.pone.0004579
Piccinni MP, Beloni L, Livi C et al (1998) Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 4:1020–1024. https://doi.org/10.1038/2006
Piccinni MP, Romagnani S (1996) Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Immunol Res 15:141–150
Wolfson ML, Muzzio DO, Ehrhardt J et al (2016) Expression analysis of cannabinoid receptors 1 and 2 in B cells during pregnancy and their role on cytokine production. J Reprod Immunol 116:23–27. https://doi.org/10.1016/j.jri.2016.05.001
del Arco I, Muñoz R, Rodríguez De Fonseca F et al (2000) Maternal exposure to the synthetic cannabinoid HU-210: effects on the endocrine and immune systems of the adult male offspring. Neuroimmunomodulation 7:16–26
Lombard C, Hegde VL, Nagarkatti M, Nagarkatti PS (2011) Perinatal exposure to Delta9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. J Pharmacol Exp Ther 339:607–617. https://doi.org/10.1124/jpet.111.181206
Miller JM, Goodridge C (2000) Antenatal marijuana use is unrelated to sexually transmitted infections during pregnancy. Infect Dis Obstet Gynecol 8:155–157. https://doi.org/10.1155/S106474490000020X
Tindall B, Cooper DA, Donovan B et al (1988) The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med 18:8–15
Bredt BM, Higuera-Alhino D, Shade SB et al (2002) Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42:82S–89S
Di Franco MJ, Sheppard HW, Hunter DJ et al (1996) The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men’s Health Study. Ann Epidemiol 6:283–289
Abrams DI, Hilton JF, Leiser RJ et al (2003) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139:258–266
Noe SN, Nyland SB, Ugen K et al (1998) Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol 437:223–229
Peterson PK, Gekker G, Hu S et al (2004) Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 147:123–126
Rock RB, Gekker G, Hu S et al (2007) WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol 2:178–183. https://doi.org/10.1007/s11481-006-9040-4
Roth MD, Tashkin DP, Whittaker KM et al (2005) Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 77:1711–1722. https://doi.org/10.1016/j.lfs.2005.05.014
Rizzo MD, Crawford RB, Henriquez JE et al (2018) HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-γ-inducible protein 10 levels compared with nonusing HIV patients. AIDS 32:419–429. https://doi.org/10.1097/QAD.0000000000001704
Ishida JH, Peters MG, Jin C et al (2008) Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 6:69–75. https://doi.org/10.1016/j.cgh.2007.10.021
Hézode C, Roudot-Thoraval F, Nguyen S et al (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42:63–71. https://doi.org/10.1002/hep.20733
Teixeira-Clerc F, Julien B, Grenard P et al (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12:671–676. https://doi.org/10.1038/nm1421
Lavanco G, Castelli V, Brancato A et al (2018) The endocannabinoid-alcohol crosstalk: recent advances on a bi-faceted target. Clin Exp Pharmacol Physiol. https://doi.org/10.1111/1440-1681.12967
Karsak M, Gaffal E, Date R et al (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494–1497. https://doi.org/10.1126/science.1142265
Hegde VL, Hegde S, Cravatt BF et al (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 74:20–33. https://doi.org/10.1124/mol.108.047035
Pandey R, Hegde VL, Singh NP et al (2009) Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam Horm 81:487–504. https://doi.org/10.1016/S0083-6729(09)81019-4
Nagarkatti M, Rieder SA, Hegde VL et al (2010) Do cannabinoids have a therapeutic role in transplantation? Trends Pharmacol Sci 31:345–350. https://doi.org/10.1016/j.tips.2010.05.006
Hegde VL, Nagarkatti PS, Nagarkatti M (2011) Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One 6:e18281. https://doi.org/10.1371/journal.pone.0018281
Pandey R, Hegde VL, Nagarkatti M, Nagarkatti PS (2011) Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model. J Pharmacol Exp Ther 338:819–828. https://doi.org/10.1124/jpet.111.182717
Katchan V, David P, Shoenfeld Y (2016) Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev 15:513–528. https://doi.org/10.1016/j.autrev.2016.02.008
Baker D, Jackson SJ, Pryce G (2007) Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 152:649–654. https://doi.org/10.1038/sj.bjp.0707458
Antonucci R, Zaffanello M, Puxeddu E et al (2012) Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab 13:474–490
Li D-K, Liu L, Odouli R (2003) Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 327:368. https://doi.org/10.1136/bmj.327.7411.368
Nakhai-Pour HR, Broy P, Sheehy O, Bérard A (2011) Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 183:1713–1720. https://doi.org/10.1503/cmaj.110454
Young IR, Thorburn GD (1994) Prostaglandin E2, fetal maturation and ovine parturition. Aust N Z J Obstet Gynaecol 34:342–346
Koren G, Florescu A, Costei AM et al (2006) Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 40:824–829. https://doi.org/10.1345/aph.1G428
Hahn M, Baierle M, Charão MF et al (2017) Polyphenol-rich food general and on pregnancy effects: a review. Drug Chem Toxicol 40:368–374. https://doi.org/10.1080/01480545.2016.1212365
Zielinsky P, Piccoli AL, Vian I et al (2013) Maternal restriction of polyphenols and fetal ductal dynamics in normal pregnancy: an open clinical trial. Arq Bras Cardiol 101:217–225. https://doi.org/10.5935/abc.20130166
Vian I, Zielinsky P, Zílio AM et al (2017) Increase of prostaglandin E2 in the reversal of ductal constriction after polyphenol restriction. Ultrasound Obstet Gynecol. https://doi.org/10.1002/uog.18974
Ammenheuser MM, Berenson AB, Babiak AE et al (1998) Frequencies of hprt mutant lymphocytes in marijuana-smoking mothers and their newborns. Mutat Res 403:55–64
Feinshtein V, Erez O, Ben-Zvi Z et al (2013) Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol 209:573.e1–573.e15. https://doi.org/10.1016/j.ajog.2013.08.005
Robison LL, Buckley JD, Daigle AE et al (1989) Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer 63:1904–1911
Grufferman S, Schwartz AG, Ruymann FB, Maurer HM (1993) Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 4:217–224
Kuijten RR, Bunin GR, Nass CC, Meadows AT (1990) Gestational and familial risk factors for childhood astrocytoma: results of a case–control study. Cancer Res 50:2608–2612
Hall W, MacPhee D (2002) Cannabis use and cancer. Addiction 97:243–247
Bluhm EC, Daniels J, Pollock BH et al (2006) Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children’s Oncology Group (United States). Cancer Causes Control 17:663–669. https://doi.org/10.1007/s10552-005-0580-3
Moeller MR, Doerr G, Warth S (1992) Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking study and forensic cases. J Forensic Sci 37:969–983
Frazee CC, Kiscoan M, Garg U (2010) Quantitation of total 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in urine and blood using gas chromatography-mass spectrometry (GC–MS). Methods Mol Biol 603:137–144. https://doi.org/10.1007/978-1-60761-459-3_13
Fu S, Lewis J (2008) Novel automated extraction method for quantitative analysis of urinary 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). J Anal Toxicol 32:292–297
Wall ME, Perez-Reyes M (1981) The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S–189S
Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770–1804. https://doi.org/10.1002/cbdv.200790152
Schwilke EW, Schwope DM, Karschner EL et al (2009) Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 55:2180–2189. https://doi.org/10.1373/clinchem.2008.122119
Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86–95. https://doi.org/10.3109/03602532.2013.849268
Sharma P, Murthy P, Bharath MMS (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 7:149–156
de Mantovani C, Silva JPE, Forster G et al (2018) Simultaneous accelerated solvent extraction and hydrolysis of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide in meconium samples for gas chromatography-mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci 1074–1075:1–7. https://doi.org/10.1016/j.jchromb.2018.01.009
Koch M, Dehghani F, Habazettl I et al (2006) Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. J Neurochem 98:267–278. https://doi.org/10.1111/j.1471-4159.2006.03873.x
Burstein SH, Audette CA, Doyle SA et al (1989) Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J Pharmacol Exp Ther 251:531–535
Tius MA, Kannangara GSK, Kerr MA, Grace KJS (1993) Halogenated cannabinoid synthesis. Tetrahedron 49:3291–3304. https://doi.org/10.1016/S0040-4020(01)90158-9
Turcotte C, Chouinard F, Lefebvre JS, Flamand N (2015) Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol 97:1049–1070. https://doi.org/10.1189/jlb.3RU0115-021R
Stebulis JA, Johnson DR, Rossetti RG et al (2008) Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci 83:666–670. https://doi.org/10.1016/j.lfs.2008.09.004
Zurier RB, Sun Y-P, George KL et al (2009) Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J 23:1503–1509. https://doi.org/10.1096/fj.08-118323
Takeda S, Jiang R, Aramaki H et al (2011) Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors. J Pharm Sci 100:1206–1211. https://doi.org/10.1002/jps.22354
Harvey D (1991) Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR (ed) Biochemistry and physiology of substance abuse. CRC Press, Boca Raton, pp 279–365
Ujváry I, Hanuš L (2016) Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 1:90–101. https://doi.org/10.1089/can.2015.0012
Mechoulam R, Tchilibon S et al (2010) United States Patent: 7759526—pharmaceutical compositions comprising cannabidiol derivatives. http://patft.uspto.gov. Accessed 5 Oct 2018
Chimalakonda KC, Seely KA, Bratton SM et al (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174–2184. https://doi.org/10.1124/dmd.112.047530
ElSohly MA, Gul W, Elsohly KM et al (2011) Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 35:487–495
Brents LK, Reichard EE, Zimmerman SM et al (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917. https://doi.org/10.1371/journal.pone.0021917
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci 97:45–54. https://doi.org/10.1016/j.lfs.2013.09.017
Tai S, Fantegrossi WE (2017) Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. Curr Top Behav Neurosci 32:249–262. https://doi.org/10.1007/7854_2016_60
Rajasekaran M, Brents LK, Franks LN et al (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100–108. https://doi.org/10.1016/j.taap.2013.03.012
Bird A (2007) Perceptions of epigenetics. Nature 447:396–398. https://doi.org/10.1038/nature05913
Martin C, Zhang Y (2007) Mechanisms of epigenetic inheritance. Curr Opin Cell Biol 19:266–272. https://doi.org/10.1016/j.ceb.2007.04.002
Szutorisz H, Hurd YL (2016) Epigenetic effects of cannabis exposure. Biol Psychiatry 79:586–594. https://doi.org/10.1016/j.biopsych.2015.09.014
Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M (2015) Epigenetic regulation of immunological alterations following prenatal exposure to marijuana cannabinoids and its long term consequences in offspring. J Neuroimmune Pharmacol 10:245–254. https://doi.org/10.1007/s11481-015-9586-0
Hegde VL, Tomar S, Jackson A et al (2013) Distinct MicroRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by Δ9-tetrahydrocannabinol in vivo regulation of CCAAT/enhancer-binding protein α by microRNA-690. J Biol Chem 288:36810–36826
Yang X, Hegde VL, Rao R et al (2014) Histone modifications are associated with Delta(9)-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses. J Biol Chem 289:18707–18718. https://doi.org/10.1074/jbc.M113.545210
Szutorisz H, Hurd YL (2018) High times for cannabis: epigenetic imprint and its legacy on brain and behavior. Neurosci Biobehav Rev 85:93–101. https://doi.org/10.1016/j.neubiorev.2017.05.011
Möhnle P, Schütz SV, Schmidt M et al (2014) MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun 451:516–521. https://doi.org/10.1016/j.bbrc.2014.08.008
Chandra LC, Kumar V, Torben W et al (2014) Chronic administration of Δ9-tetrahydrocannabinol induces intestinal anti-inflammatory microRNA expression during acute SIV infection of rhesus macaques. J Virol 89:1168–1181. https://doi.org/10.1128/JVI.01754-14
Tomasiewicz HC, Jacobs MM, Wilkinson MB et al (2012) Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry 72:803–810. https://doi.org/10.1016/j.biopsych.2012.04.026
Rotter A, Bayerlein K, Hansbauer M et al (2013) CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. Eur Addict Res 19:13–20. https://doi.org/10.1159/000338642
Hegde VL, Nagarkatti M, Nagarkatti PS (2010) Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 40:3358–3371. https://doi.org/10.1002/eji.201040667
Bronte V (2009) Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 39:2670–2672. https://doi.org/10.1002/eji.200939892
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. https://doi.org/10.1038/nri2506
Mecha M, Feliú A, Machín I et al (2018) 2-AG limits Theiler’s virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. Glia 66:1447–1463. https://doi.org/10.1002/glia.23317
Jackson AR, Nagarkatti P, Nagarkatti M (2014) Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS One 9:e93954. https://doi.org/10.1371/journal.pone.0093954
Perera F, Herbstman J (2011) Prenatal environmental exposures, epigenetics, and disease. Reprod Toxicol 31:363–373. https://doi.org/10.1016/j.reprotox.2010.12.055
Thompson RF, Einstein FH (2010) Epigenetic basis for fetal origins of age-related disease. J Womens Health (Larchmt) 19:581–587. https://doi.org/10.1089/jwh.2009.1408
Acknowledgements
Catherine Dong and Amy Harrington received the Magellan Fellowships from the University of South Carolina. The authors’ research on cannabinoids was supported by the US National Institutes of Health (Grants DA034892 to VLH and DA020531 to KYV).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dong, C., Chen, J., Harrington, A. et al. Cannabinoid exposure during pregnancy and its impact on immune function. Cell. Mol. Life Sci. 76, 729–743 (2019). https://doi.org/10.1007/s00018-018-2955-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-018-2955-0